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Abstract 
 It has been shown that the mammalian target of rapamycin (mTOR) pathway, which 
regulates cell growth and proliferation, is aberrant in many hematological malignancies. 
Rapamycin inhibits mTOR signaling which regulates cell growth and cell cycle progression. 
This study sought to determine the effects of mTOR inhibitors on the cell sizes of normal and 
neoplastic cells and to determine ultrasonic sensitivity of normal and neoplastic cells treated with 
mTOR inhibitors. The effects of rapamycin (rapa), an extensively studied natural product that 
affects cell cycle entry by inhibiting mTORC1, and its analogs temsirolimus (tems) and 
everolimus (eve), were examined on leukemic cell lines (U937: Human monocytic leukemia, 
THP-1: Human acute monocytic lymphoma, K562: Human chronic myelogenous leukemia, and 
MOLT-4, Human acute lymphoblastic leukemia) in combination with 20kHz ultrasound. Each 
cell line was treated for 48 hours with each analog before being exposed to ultrasound. By using 
low frequency ultrasound of 5 pulses (0.6 seconds of ultrasound and 0.4 seconds without 
ultrasound) at 20 kHz and 30% amplitude (60W), we determined that as the concentrations of 
Rapa, Eve, and Tems (2, 20, and 50nM) increased, there is usually the most sonic damage 
observed in U937, MOLT-4, K562, and THP-1 cells. The most preferentially damaged cell line 
is K562 by all of the analogs and with all the concentrations used. In addition, larger cells were 
more susceptible to ultrasonic damage than were smaller cells. Further, there are no significant 
differences among the three analogs in the potentiation of ultrasonic damage. This preliminary 
therapeutic approach involving the use of ultra-sound in combination with mTOR inhibitors 
might eventually provide an improved approach to the treatment of leukemia and other 
hematological malignancies in a clinical setting.  
Key words: Low frequency ultrasound, mTOR, Rapamycin, Everolimus, Temsirolimus, Human Leukemia 
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Executive Summary 
 
 Common treatments for cancers include radiation, chemotherapy, immunotherapy, 
hematopoietic stem cell transplants, gene therapy, and host response modification using 
hormones, cytokines, and other bio-therapeutic agents. These alternative modalities are used 
alone or in combination. I propose to add treatment with continuous or pulsed low frequency 
ultra-sound as an additional cancer treatment modality. Low-frequency ultrasound as a 
physically based cancer treatment can circumvent chemically based drug-resistance and can be 
controlled and finely modulated from outside of the patient. Sirolimus, also known as 
Rapamycin, and analogs of Rapamycin, Everolimus and Temsirolimus, are used to treat human 
leukemia cell lines in vitro altering the size, proliferative capacity, and viability of the treated 
cells. We determine the ability of low-frequency ultrasound to produce damage to leukemia cells 
treated with Rapamycin or analogs in comparison with the effects of low frequency ultra-sound 
on untreated and treated leukemia cells. In this work we attempt to determine the effects of 
Rapamycin (Rapa), Temsirolimus (Tems) and Everolimus (Eve) on human leukemic cell lines 
(U937: monocytic leukemia, THP-1: acute monocytic lymphoma, K562: chronic myelogenous 
leukemia, and MOLT-4, an acute lymphoblastic leukemia) non-sonicated or sonicated with low 
frequency ultrasound for 5 pulses (0.6 seconds of ultrasound and 0.4 seconds without ultrasound) 
at 20kHz and 30% amplitude (60W). The cells were treated with each chemotherapeutic agent at 
2 nM, 20 nM, 0r 50 nM for 48 hours prior to sonication to explore whether preferential damage 
is dependent on concentration and duration of treatment prior to sonication. 
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Preface  
 
  As a student, I am constantly looking for ways to acquire the knowledge and skills in 
order to help people. I have a strong passion to become a physician and alleviate human 
suffering because I hope to someday bring smiles to my patients with a simple caring touch of 
understanding. Ever since I was little, I knew I wanted to give back to the medical field as a 
doctor because they are the ones that saved my mom’s life from breast cancer. As my mom 
continues to battle breast cancer, her fight continues to have a hug impact on my life and 
influences my decision to do cancer research at Syracuse University.  
        For my undergraduate education, I have specifically chosen biotechnology over standard 
biology degrees because of its extra emphasis on learning about public policy, management and 
engineering. My other motive to pursuing my biotechnology major is essentially because of the 
applied concept behind it. It truly helps one to take theories and put them into practical use. 
Along with my biotechnology major, I have chosen to pursue Arabic and Middle Eastern studies 
because of my Egyptian descent. 
        At Syracuse University, I was granted the opportunity to do extracurricular cancer 
research with Dr. Thomas Fondy and his team. We are examining the use of ultrasound 
irradiation and chemotherapeutic agents as potential treatment modalities to produce a 
substantial synergistic effect amongst leukemic cell lines (U937: Human monocytic leukemia, 
THP-1: Human acute monocytic lymphoma, K562: Human chronic myelogenous leukemia, and 
MOLT-4, Human an acute lymphoblastic leukemia).  
After my undergraduate education I wish to continue to acquire the knowledge and skills 
in medical school in order to help people. I look forward to seizing this opportunity of a lifetime. 
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Advice to Future Honors Students  
 Be prepared to grow as an individual no matter what. You will hit those turning points 
throughout your undergraduate career that persuade you to constantly question your inner 
principles. But, this is all part of the process of growing up. You will grow to become a stronger 
and smarter individual, then when you first arrived to college. Enjoy the process and I wish you 
all the best. P.s. - Remember to try new things and stick with the ones you love! 
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Chapter 1: Introduction  
The first discovery of leukemia was independently observed by researchers John Hughes 
Bennett and Rudolph Virchow (Piller, 2008).   Leukemia occurs worldwide and represents about 
5 percent of all cancer. The Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute lists leukemia as the seventh leading cause of cancer death in the 
United States. The number of deaths was 6.9 per 100,000 men and women per year based on 
2009-2013 deaths. Furthermore, leukemia has the capability to strike anyone, at any time, at any 
age. In 2016 the National Cancer Institute estimated there will be 60,140 new cases of leukemia 
in the United States and an estimated 24,400 people will die from this disease. Leukemia is 
slightly more common in men than women with a male/female ratio to be about 1.7:1.  
Leukemia is cancer of the blood cells, denoting a group of malignant disorders in the 
blood-forming cells. The bone marrow (where blood cells are made) malfunctions and produces 
abnormal white (leukemic) cells, which damage the function of other essential blood cells (Piller, 
2008). In the marrow, at least 200 billion red cells, 10 billion white cells, and over 400 billion 
platelets are produced in the marrow each day (Piller, 2008). In normal conditions, circulating 
blood has approximately 1,000 red cells to each white cell (Piller, 2008). However, in leukemia, 
normal production of blood cells fails. White blood cells reproduce abnormally and create poorly 
developed cells or immature blasts. These leukemic cells overpopulate the bone marrow, enter 
the bloodstream and lymph system, and infiltrate organs and glands, causing them to enlarge and 
malfunction. The bone marrow becomes unable to produce sufficient levels of red cells and 
platelets; consequently, the balance of the blood cell population is seriously disturbed, and the 
body’s defenses based on white blood cells and platelets are rendered ineffective. 
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Chapter 2: Literature Search 
The mammalian target of rapamycin (mTOR) has received considerable attention as a 
potential target for cancer chemotherapy, especially in endocrine therapy in breast cancer. 
According to the National Cancer Institute’s online dictionary (2012), endocrine therapy is 
referred to as hormonal therapy which focuses on slowing or stopping the growth of a hormone-
sensitive tumor by blocking the body’s ability to produce hormones such as estrogen and 
progesterone, which may promote the growth of some breast cancers. Previous research has 
indicated estrogen-induced breast tumor cells proliferation require mTOR signaling (Boulay et 
al, 2005). As such, most of the research involving the mTOR pathway has been directed toward 
inhibiting the mTOR pathway as a key oncoprotein. mTOR as a member of the 
phosphatidylinositol 3-kinaserelated kinase protein (PIKK) family, is a serine/threonine protein 
kinase which regulates cell growth, cell proliferation, cell motility, cell survival, protein 
synthesis, and transcription, and is also a constituent of the PI3K/AKT/mTOR (PI3K: 
phosphatidylinositol-4, 5-bisphosphate 3-kinase; AKT: protein kinase B) pathway (Guertin and 
Sabatini, 2007). Further, mTOR serves as part of an evolutionarily conserved signaling pathway 
that controls the cell cycle in response to changing nutrient levels (Nakamura, 2014). 
Dysregulation of the mTOR pathways has been linked to human diseases such as diabetes, 
obesity, depression, and certain cancers (Nakamura, 2014).      
The rapamycin actions are regulated through specific inhibition of the mTOR protein 
kinase. Inhibition of the mTOR pathways prevents proliferation of normal cells, but not the 
proliferation of cancer cells due to their elevated expression of the mTOR protein. Further, a 
central component for development and homeostasis for cancer involve the formation of new 
blood vessels, or angiogenesis (Veikkola and Alitalo, 1999). These blood vessels supply growth 
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to the tumor, and the chemicals released by the tumor engage other host cells near the tumor 
causing the cancer to spread.  
 
 
Figure 1: mTORC1 and mTORC2 Pathway. mTORC1 consists of the mTOR, Raptor, and 
GβL. mTORC1 acts on cell size. mTORC2 consists of mTOR, Rictor, and GβL. mTORC2 acts 
on cell proliferation (number). Lower concentrations of rapamycin and its analogs can inhibit 
only mTORC1. Higher concentrations of rapamycin and its analogs can inhibit both mTORC1 
and mTORC2 
 
 Therapeutic ultrasound is an emerging field with many medical applications. In previous 
clinical studies, ultrasound was used to provide the ability to localize the deposition of acoustic 
energy within the body, which can cause tissue necrosis (cell death) and hemostasis (interruption 
of blood flow). Ultrasound is a mechanical wave with periodic vibrations of particles in a 
continuous, elastic medium at frequencies equal to or greater than 20 kHz. In liquids, its velocity 
of about 1000–1600 m/s translates into the wavelength range from micrometers to centimeters 
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(Rosenthal et al., 2004). Furthermore, cavitation occurs when applying high intensity ultrasound 
to liquids. A sinusoidal pressure is superimposed on the constant ambient pressure in generating 
cavitation.  Cavitation is a continual process of gas bubble nucleation, growth, and collapse as a 
result of intense ultrasonic waves. During the negative pressure cycle, the liquid is pulled apart at 
sites containing a gaseous impurity, which is known as “weak spots” in the fluid (Brennen, 
1995). The number of bubbles produced during this rarefaction cycle is proportional to the 
density of such weak spots present in the fluid (Brennen, 1995). Bubble collapse in liquids 
results in an immense concentration of energy from the conversion of kinetic energy of liquid 
motion into heating of the contents of the bubble (Suslick et al, 1999). It is this energy that 
disrupts the cell membrane of cells to cause cell rupture and lysis. 
Indirect sonication is used predominantly to avoid cross-contamination, aerosolization, 
and foaming of the sample (Hielscher, 1999). Indirect sonication describes coupling of 
ultrasound waves via ultrasonic bath through the test tube’s wall into the sample liquid 
(Hielscher, 1999). The ultrasonic energy is transmitted from the horn, up through the water and 
into a vessel or multiple sample tubes (Heilscher, 1999). As indirect sonication of the ultrasonic 
energy is transmitted via the wall of the sample tube or beaker into the medium, the ultrasonic 
intensity that is finally coupled into the sample liquid is quite low (Hielscher, 1999). The two 
variables on the cell sonicator are frequency and amplitude. Higher ultrasonic frequencies lead to 
the production of smaller cavitation bubbles as compared with lower frequencies. Size correlates 
with the energy required to produce a cavitation bubble and its energy released. In other words, 
more energy is required to produce larger cavitation bubbles. At 20 kHz ultrasound frequency, 
the bubbles generated are relatively large. The collapse produced results in strong shockwaves 
which can be later used for mechanical shearing applications such as emulsification (Leong et al, 
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2009). Increasing ultrasonic power results increases the quantity of cavitation bubbles but has no 
effect on bubble size (Fuchs, 2011). Thus, increasing ultrasonic frequency, while delivering the 
same ultrasonic power, results in a larger number of smaller cavitation bubbles (Fuchs, 2011). 
Overall, this is a quite attractive feature from a clinical standpoint and has led to considerable 
experimentation of ultrasound for medical purposes.  
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Chapter 3: Inquiry 
This study could provide a new approach to management of cancer. Time after time, 
patients that are diagnosed with cancer are left to be fighting the disease with harsh treatment 
modalities in order to remove the cancer. Using ultrasound irradiation will provide an alternate 
method. In my research, I am striving to enhance the effects of ultrasonic irradiation by using 
anticancer drugs, Rapamycin (Rapa) and its analogs – Temsirolimus (Tems) and Everolimus 
(Eve) to treat leukemic cell lines. The leukemic cells lines used for this work are: U937 (Human 
monocytic leukemia), THP-1, (Human acute monocytic lymphoma), K562 (Human chronic 
myelogenous leukemia), and MOLT-4 (Human acute lymphoblastic leukemia). I proposed that 
by regulating the concentration of rapamycin and its analogs, the cell susceptibility of cancer 
cells to ultrasonic damage may be enhanced. In order to confirm this hypothesis, conclusive 
evidence needs to be collected before the role of ultrasound irradiation and rapamycin’s 
anticancer effect can be evaluated. 
Questions to assess in my research: 
• What effect does rapamycin have on cell proliferation? 
• Do mTOR inhibitors preferentially damage cells in combination with low-frequency 
ultrasound?  
• What are the effects of rapamycin alone or in combination with low-frequency ultrasound on 
cell viability? 
• Which of the three mTOR inhibitors causes the greatest damage in combination with 
ultrasound?  
• Is the sonic damage concentration dependent? 
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Rapamycin and its analogs 
 
Image retrivved by Google Images by searching the respective name of compound  
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Chapter 4: Materials Methods 
Cell Culture  
 Human myelomonocytic lymphoma U937 cells (ATCC® CRL- 1593.2) were placed at 
5.2 × 104 viable cells/ml in 20 % heat-inactivated fetal bovine serum (FBS) in Iscove’s medium 
without glutamine, with the following added: 200 units/ml penicillin, 200 μg/ml streptomycin, 
100 μg/ml gentamicin sulfate, 40 μM glutamine (50 μl of 2 mM glutamine per 5 ml medium), 
and 50 μl of amphotericin B (2.5 μg/ml concentration) per 5 ml of medium. K562, Molt-4, and 
THP1 human leukemia (ATCC® CCL-243, CRL-1582, and TIB-202) were cultured under the 
same conditions.  These cell lines were retrieved from the State University of New York Upstate 
Medical University (Syracuse, NY, USA). The cells were incubated in 5 % CO2 in a humidified 
chamber at 37 °C. Viability was assessed by 0.4 % trypan blue stain in isotonic saline, followed 
by cell counting and sizing using a Z2 Beckman-Coulter® Particle Count and Size Analyzer 
(Beckman Coulter Inc., Brea, CA, USA), along with a Bio-Rad® TC20 Automated Cell Counter 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Extent of multinucleation after treatment with 
rapamycin with Wright stain. 
Drugs 
Rapamycin (Sigma-Aldrich Corp., St. Louis, MO, USA) was prepared in 40 μM stock solutions 
using 95 % EtOH (Sigma-Aldrich Corp.). Rapamycin analogs everolimus and temsirolimus were 
prepared using the same conditions. Cell size, viability, and proliferation rates were determined 
by the cell counters. Vehicle controls of 95 % EtOH were tested in parallel with the rapamycin-
treated cells. 
Ultrasound apparatus and intensity measurement  
For the sonication, I will be using a 20 kHz Branson Sonifier 250 (60mm diameter cup) 
and 24mm Mylar Bottom Glass Bottle. The ultrasound apparatus has a 2 cm horn tuned to 3 cm 
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of degassed water above the horn. There was 30% amplitude (60 W). Water was heated to about 
37 °C between each sonication.  
Untreated U937, THP-1, K562, MOLT-4; Rapa (2nM, 20nM, 50nM); Eve (2nM, 20nM, 
50nM); Tems (2nM, 20nM, 50nM) control counts are taken twice duplicate on TC20 and Z2. 
Then, sonicate 3ml of untreated U937, THP-1, K562, MOLT-4; Rapa (2nM, 20nM, 50nM); Eve 
(2nM, 20nM, 50nM); Tems (2nM, 20nM, 50nM) cells in glass vial. The next step is to take cell 
count on TC20 and Z2 after sonication (have 2 counts per sample). The following step is to take 
untreated U937, THP-1, K562, MOLT-4; Rapa (2nM, 20nM, 50nM); Eve (2nM, 20nM, 50nM); 
Tems (2nM, 20nM, 50nM) control count on TC20 and Z2 after all sonication is done. TC20 used 
a 1:1 dilution untreated U937, THP-1, K562, MOLT-4; Rapa (2nM, 20nM, 50nM); Eve (2nM, 
20nM, 50nM); Tems (2nM, 20nM, 50nM) cells : Trypan Blue. The Z2 used 1:201 dilution 
untreated U937, THP-1, K562, MOLT-4; Rapa (2nM, 20nM, 50nM); Eve (2nM, 20nM, 50nM); 
Tems (2nM, 20nM, 50nM) cells : Isoton 
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Measurement of cell survival 
A BioRad TC20 automated hemocytometer was used to determine cell viability using trypan 
blue dye exclusion by viable cells. A Beckman Z2 Coulter Counter was used to determine total 
cell numbers and size distribution. 
Statistical Analysis  
All of the data are presented as the mean ± SD. The differences between groups were assessed 
with Student’s t test at a 95% confidence interval; P < 0.05 was considered to be significant. The 
assessment of synergy was performed by two-way factorial ANOVA. 
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Chapter 5: Results 
 All three mTOR inhibitors decrease the mean cell diameter of U937 monocytc leukemia 
cells. The various concentrations of inhibitors (green, blue, and black lines) are shifted to the left 
relative to the untreated control (red line) (Figure 6). As you increase the concentration of mTOR 
inhibitors it produces less viable cells even though it does not increase sonic sensitivity (Figure 
7). Sonication of the U937 monocytic leukemia cells reduced the cell number (Figure 6). This 
reduction becomes greater as the means cell diameter increases (Figure 6). Sonicated U937 
monocytic leukemia treated with 20 nM everolimus showed the least survivability compared 
with the untreated unsonicated control cells (Figure 3, 4 & 5). Further, there was no significant 
difference between analogs on the survivability of each leukemia cell line (Figure 3, 4 & 5). In 
figure 6, the temsirolumus unsonicated graph demonstrated a higher peak for unsonicated 20 nM, 
which could mean there was higher cell density to begin with prior to adding the 20 nM 
temsirolimus. Also, in figure 6, higher left peaks in all of the sonicated graphs indicate debris 
that is caused by sonication. As the cell membrane is lyses particles of the membrane are 
released.   
 
 
Figure 2: Average Cell Diameters of U937, K562, MOLT-4, & THP-1 unsonicated and untreated 
taken by Z2 Beckman-Coulter® Particle Count and Size Analyzer 
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Figure 4: Effect of 2, 20, and 50 nM of Everolimus on the inhibition of proliferation and on 
sonic sensitivity to U937 (AML), THP-1 (AML), K562 (CML), and MOLT-4 (ALL) Human 
leukemia cell lines. Numbers calculated by Beckman Coulter Z2 Counter using a 20 kHz System 
at 30% Amplitude, 5 x 0.6 sec pulses with 0.4 sec spacing, glass vials, n=4.  
Figure 3: Effect of 2, 20, and 50 nM of Rapamycin on the inhibition of proliferation and on sonic 
sensitivity to U937 (AML), THP-1 (AML), K562 (CML), and MOLT-4 (ALL) Human leukemia 
cell lines. Numbers calculated by Beckman Coulter Z2 Counter using a 20 kHz System at 30% 
Amplitude, 5 x 0.6 sec pulses with 0.4 sec spacing, glass vials, n=4.  
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Figure 5: Effect of 2, 20, and 50 nM of Temsirolimus on the inhibition of proliferation and on 
sonic sensitivity to U937 (AML), THP-1 (AML), K562 (CML), and MOLT-4 (ALL) Human 
leukemia cell lines. Numbers calculated by Beckman Coulter Z2 Counter using a 20 kHz System 
at 30% Amplitude, 5 x 0.6 sec pulses with 0.4 sec spacing, glass vials, n=4.  
 
Figure 6: Cell size distribution calculated by Beckman Coulter Z2 Counter for U937 monocytic 
leukemia treated with 2, 20, and 50 nM of Rapamycin, Everolimus, and Temsirolimus. A&B- 
Unsonicated and sonicated Rapamycin treated, respectively. C&D- Unsonicated and sonicated 
everolimus- treated respectively. E&F- Unsonicated and sonicated temsirolimus-treated, respectively. 
Red-Untreated control. Green- 2nM. Blue- 20 nM. Black- 50 nM 
14 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effect of mTOR inhibitors (rapamycin, everolimus, temsirolimus) on the viability 
of U937 human acute monocytic leukemia 
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Chapter 6: Discussion 
 mTOR inhibitors appear to have a dose dependent effect on the inhibition of proliferation 
on U937, THP-1, K562, and MOLT-4 leukemia cell lines. Treatment with pulsed low frequency 
20 kHz ultrasound further decreases cell number by inducing cell lysis. 2nM temsirolimus 
caused the most cell lysis in U937 cells and THP-1 cells, whereas 2nM everolimus caused the 
cell lysis in K562 cells. Viability of unsonicated U937 does not change as mTOR inhibitor 
concentration is increased from 2nM to 50nM. Effects of mTOR inhibitors on the inhibition of 
proliferation of leukemia cells can be combined with the effects of 20 kHz pulsed low frequency 
ultrasounds on cell lysis to decrease the total number of U937, THP-1, K562, and MOLT-4 cells. 
U937 acute monocytic leukemia cells that remain after sonication become increasingly less 
viable as the concentration of mTOR inhibitors are increased. MOLT-4 cells appear to be 
significantly susceptible to ultrasonic cell lysis whereas U937 cells appear to be least sensitive. 
mTOR inhibitors do not significantly change the sonic sensitivity in any of the examined cell 
lines.  
 For future research, it would be beneficial to introduce the combination of cytochalasin 
B, a microfilament directed agent, in combination with rapamycin. According to previous 
clinical studies, cytochalasin B is known to produce enlarged and multinucleated cells 
(Trendowski et al, 2015). Therefore, this could potentially increase susceptibility to ultrasonic 
damage. Furthermore, in vivo work with mice would be useful in determining how a live animal 
tolerates ultrasound. For humans, the sonication of leukemia cells can be administered via 
hemodialysis as indicated in the image below.  
16 
 
 
 
 
 
 
 
 
 
 
 
For extracorpeal blood sonication, the patient’s blood is to be pumped outside of the body 
to provide an opportunity for leukemia cells to be sonicated.  
 
Image retrieved from http://mountbakerkidneycenter.org/treatment/hemodialysis/ 
Potential location of sonication device. 
This could be placed in multiple locations.  
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Chapter 7: Additional Work Completed 
 
Concomitant Effects of mTOR inhibitors (2 nM Rapamycin) with cytoskeletal-direct agent 
(2 um Cytochalasin B) on U937 cells before and after Pulsed Sonication with 20 kHz 
System (60 W) 
 
 Stemming off of the previous researc, I had the time to assess the addition of cytochalasin 
B (CB) and its affect with rapamycin. I wanted to assess how much more damage is caused after 
sonication to the treated cells? I am using U937 human monocytic leukemia cell lines because 
previous research has indicated that this cell line reveals the most reliable data. In lab we have 
already seen the effect of rapamycin and CB on cell size of U937 cells without sonication 
(Trendowski et al, 2015). 
 
 
  
 The procedures protocols were set up the same way as the previous experiment.  
Figure 4. Effects of rapamycin and cytoskeletal-directed agents on cell size 
of U937 human monocytic leukemia cells (Trendowski et al, 2015, p. 1169). 
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Control counts of untreated U937 cells; Rapa (2 nM), Cytochalasin B (CB) (2 uM), 2 nM Rapa + 
2 uM CB were taken in a duplicate manner on TC20 and Z2. 2 uM CB-treated U937 cells and 2 
nM rapamycin treated cells were treated for 48 hours. Then, sonicate 3ml of untreated U937 
Rapa (2 nM), Cytochalasin B (CB) (2 uM), 2 nM Rapa + 2 um CB, cells in glass vial. Cell count 
was taken on TC20 and Z2 after sonication, 2 counts per sample. Untreated U937; Rapa (2 nM), 
Cytochalasin B (CB) (2 uM), 2 nM Rapa + 2 uM CB control count on TC20 and Z2 was also 
taken after all sonication was done. The TC20 used 1:1 dilution untreated U937; Rapa (2 nM), 
Cytochalasin B (CB) (2 uM), 2 nM Rapa + 2 uM CB: Trypan Blue. Z2 used 1:201 dilutions 
untreated U937; Rapa (2 nM), Cytochalasin B (CB) (2 uM), 2 nM Rapa + 2 um CB: Isoton. 
 
 
 
 
Figure 8: Effect of 2nM Rapamycin, 2µM cytochalasin B, or a combination on the percent 
survival of U937 human monocytic leukemia using the Beckman Coulter Z2 Counter in a 20 kHz 
system with 30% amplitude (60 W), glass vials and 5 x 0.6s of ultrasound and 0.4 seconds without 
ultrasound 
19 
 
 
 Figure 8 demonstrates that sonicating U937 cells with combination of rapamycin and 
cytochalasin B produces the most damage to the cells survival. Cytochalasin B alone creates 
more cell lysis than Rapamycin alone. The potential for increasing synergy between rapamycin 
and cytochalasin B may be due to the inhibitory effects these agents have on the microfilaments 
located in the cell’s cytoskeleton. As mentioned in my previous research , in vivo work with mice 
would be useful in determining how a live animal tolerates ultrasound with these 
chemotherapeutic agents.  
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Chapter 8: Conclusion 
 In this present study the sonic sensitivity increases as cell size increases. Introducing 
rapamycin to cytoskeletal-directed agents may induce a drug synergy effect to leukemia cells 
when low-frequency ultrasound is applied. Further characterization of the potential 
antineoplastic applications of mTOR inhibitors and cytoskeletal-directed agents in mammalian 
models is therefore crucial. The observations made by this research demonstrate a potentially 
novel therapeutic approach for leukemia, and hopefully for other cancers, which aberrantly 
express mTOR to elicit preferential damage. 
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